+关注
为爱交易
暂无个人介绍
IP属地：广东
67
关注
1
粉丝
0
主题
0
勋章
主贴
热门
为爱交易
2025-08-13
$维立志博-B(09887)$
为爱交易
2025-07-11
雨布mu
抱歉，原内容已删除
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3560770079711354","uuid":"3560770079711354","gmtCreate":1597676056771,"gmtModify":1704447495211,"name":"为爱交易","pinyin":"wajyweiaijiaoyi","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":67,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":2,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.02.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.12.11","exceedPercentage":"93.84%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.11.22","exceedPercentage":"93.79%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"1f74612b6f95455f970edd02b5316db8-2","templateUuid":"1f74612b6f95455f970edd02b5316db8","name":"收益排行","description":"Top 30%","bigImgUrl":"https://static.tigerbbs.com/50461c8139b6ca50fe2dae19aa769b25","smallImgUrl":"https://static.tigerbbs.com/c8eef504853d5a517c50d7a88fa5c1e1","grayImgUrl":"https://static.tigerbbs.com/5273727845028b8d9b65556bdcb217b9","redirectLinkEnabled":0,"redirectLink":"https://www.itigerup.com/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.07","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":5300},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":6,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":9,"crmLevelSwitch":1,"location":"广东","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":3,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":467073655357952,"gmtCreate":1755048221140,"gmtModify":1755048402604,"author":{"id":"3560770079711354","authorId":"3560770079711354","name":"为爱交易","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":9,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3560770079711354","idStr":"3560770079711354"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/09887\">$维立志博-B(09887)$</a> ","listText":"<a href=\"https://laohu8.com/S/09887\">$维立志博-B(09887)$</a> ","text":"$维立志博-B(09887)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/467073655357952","isVote":1,"tweetType":1,"viewCount":523,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":455319725596752,"gmtCreate":1752199058793,"gmtModify":1752200117007,"author":{"id":"3560770079711354","authorId":"3560770079711354","name":"为爱交易","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":9,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3560770079711354","idStr":"3560770079711354"},"themes":[],"htmlText":"雨布mu","listText":"雨布mu","text":"雨布mu","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/455319725596752","repostId":"1194298180","repostType":2,"isVote":1,"tweetType":1,"viewCount":833,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":467073655357952,"gmtCreate":1755048221140,"gmtModify":1755048402604,"author":{"id":"3560770079711354","authorId":"3560770079711354","name":"为爱交易","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":9,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3560770079711354","authorIdStr":"3560770079711354"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/09887\">$维立志博-B(09887)$</a> ","listText":"<a href=\"https://laohu8.com/S/09887\">$维立志博-B(09887)$</a> ","text":"$维立志博-B(09887)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/467073655357952","isVote":1,"tweetType":1,"viewCount":523,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":455319725596752,"gmtCreate":1752199058793,"gmtModify":1752200117007,"author":{"id":"3560770079711354","authorId":"3560770079711354","name":"为爱交易","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":9,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3560770079711354","authorIdStr":"3560770079711354"},"themes":[],"htmlText":"雨布mu","listText":"雨布mu","text":"雨布mu","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/455319725596752","repostId":"1194298180","repostType":2,"repost":{"id":"1194298180","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1752197796,"share":"https://www.laohu8.com/m/news/1194298180?lang=zh_CN&edition=full","pubTime":"2025-07-11 09:36","market":"us","language":"zh","title":"药明康德盘初大涨超9%，公司预计上半年净利润同比翻倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1194298180","media":"老虎资讯综合","summary":"7月11日（周五），药明康德盘初大涨超9%，公司预计上半年净利润同比翻倍，机构称医药研发服务的需求仍将持续增长。消息面上，药明康德发布2025年半年度业绩预告，预计上半年实现营收约207.99亿元，同比增长约20.64%；预计实现经调整归母净利润约63.15亿元，同比增长约44.43%；预计实现扣非后净利润约55.82亿元，同比增长约26.47%；预计实现归属于股东净利润约85.61亿元，同比增长约101.92%。","content":"<html><head></head><body><p>7月11日（周五），药明康德盘初大涨超9%，公司预计上半年净利润同比翻倍，机构称医药研发服务的需求仍将持续增长。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4674ebffb79ca995f7f00bcbd6443309\" tg-width=\"1139\" tg-height=\"369\"/></p><p>消息面上，药明康德发布2025年半年度业绩预告，预计上半年实现营收约207.99亿元，同比增长约20.64%；预计实现经调整归母净利润约63.15亿元，同比增长约44.43%；预计实现扣非后净利润约55.82亿元，同比增长约26.47%；预计实现归属于股东净利润约85.61亿元，同比增长约101.92%。</p><p style=\"text-align: justify;\">药明康德在半年度业绩预告中表示，公司持续聚焦独特的“一体化、端到端”CRDMO（合同研究、开发与生产）业务模式，紧抓客户对赋能需求的确定性，不断拓展新能力、建设新产能，持续优化生产工艺和提高经营效率，推动业务持续稳健增长，高效极致赋能客户并致力于将更多新药、好药带给全球病患。</p><p style=\"text-align: justify;\">公开资料显示，药明康德属于医药研发服务行业，主要为全球医药及生命科学行业提供新药研发和生产服务。公司的主营业务涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研究等领域。公司是为数不多的“一体化、端到端”的研发服务平台，能够顺应药物研发价值链，从早期药物发现阶段开始为客户提供服务，并在客户项目不断推进的过程中，从“跟随项目发展”到“跟随药物分子发展”，不断扩大服务，获得持续的增长。</p><p style=\"text-align: justify;\">分析人士认为，药明康德与全球制药行业发展以及新药研发投入密切相关，在全球制药行业蓬勃发展的推动下，公司的主营业务有着广阔的发展空间，伴随着全球各国经济的发展、全球人口总量的增长、人口老龄化程度的提高、科技进步、医疗开支上升以及大众对于健康生活的需求不断增强，预计全球制药市场规模以及对于医药研发服务的需求仍然将持续增长。</p><p style=\"text-align: justify;\">数据显示，截至2024年末，药明康德整体活跃客户约6000家。其中，持续经营业务截至年末活跃客户约5500家，持续经营业务全年新增客户约1000家，全球各地客户对公司服务的需求持续增长。截至2024年末，公司持续经营业务在手订单人民币493.1亿元，同比增长47.0%。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>药明康德盘初大涨超9%，公司预计上半年净利润同比翻倍</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n药明康德盘初大涨超9%，公司预计上半年净利润同比翻倍\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2025-07-11 09:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>7月11日（周五），药明康德盘初大涨超9%，公司预计上半年净利润同比翻倍，机构称医药研发服务的需求仍将持续增长。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4674ebffb79ca995f7f00bcbd6443309\" tg-width=\"1139\" tg-height=\"369\"/></p><p>消息面上，药明康德发布2025年半年度业绩预告，预计上半年实现营收约207.99亿元，同比增长约20.64%；预计实现经调整归母净利润约63.15亿元，同比增长约44.43%；预计实现扣非后净利润约55.82亿元，同比增长约26.47%；预计实现归属于股东净利润约85.61亿元，同比增长约101.92%。</p><p style=\"text-align: justify;\">药明康德在半年度业绩预告中表示，公司持续聚焦独特的“一体化、端到端”CRDMO（合同研究、开发与生产）业务模式，紧抓客户对赋能需求的确定性，不断拓展新能力、建设新产能，持续优化生产工艺和提高经营效率，推动业务持续稳健增长，高效极致赋能客户并致力于将更多新药、好药带给全球病患。</p><p style=\"text-align: justify;\">公开资料显示，药明康德属于医药研发服务行业，主要为全球医药及生命科学行业提供新药研发和生产服务。公司的主营业务涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研究等领域。公司是为数不多的“一体化、端到端”的研发服务平台，能够顺应药物研发价值链，从早期药物发现阶段开始为客户提供服务，并在客户项目不断推进的过程中，从“跟随项目发展”到“跟随药物分子发展”，不断扩大服务，获得持续的增长。</p><p style=\"text-align: justify;\">分析人士认为，药明康德与全球制药行业发展以及新药研发投入密切相关，在全球制药行业蓬勃发展的推动下，公司的主营业务有着广阔的发展空间，伴随着全球各国经济的发展、全球人口总量的增长、人口老龄化程度的提高、科技进步、医疗开支上升以及大众对于健康生活的需求不断增强，预计全球制药市场规模以及对于医药研发服务的需求仍然将持续增长。</p><p style=\"text-align: justify;\">数据显示，截至2024年末，药明康德整体活跃客户约6000家。其中，持续经营业务截至年末活跃客户约5500家，持续经营业务全年新增客户约1000家，全球各地客户对公司服务的需求持续增长。截至2024年末，公司持续经营业务在手订单人民币493.1亿元，同比增长47.0%。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","relate_stocks":{"603259":"药明康德","02359":"药明康德"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194298180","content_text":"7月11日（周五），药明康德盘初大涨超9%，公司预计上半年净利润同比翻倍，机构称医药研发服务的需求仍将持续增长。消息面上，药明康德发布2025年半年度业绩预告，预计上半年实现营收约207.99亿元，同比增长约20.64%；预计实现经调整归母净利润约63.15亿元，同比增长约44.43%；预计实现扣非后净利润约55.82亿元，同比增长约26.47%；预计实现归属于股东净利润约85.61亿元，同比增长约101.92%。药明康德在半年度业绩预告中表示，公司持续聚焦独特的“一体化、端到端”CRDMO（合同研究、开发与生产）业务模式，紧抓客户对赋能需求的确定性，不断拓展新能力、建设新产能，持续优化生产工艺和提高经营效率，推动业务持续稳健增长，高效极致赋能客户并致力于将更多新药、好药带给全球病患。公开资料显示，药明康德属于医药研发服务行业，主要为全球医药及生命科学行业提供新药研发和生产服务。公司的主营业务涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研究等领域。公司是为数不多的“一体化、端到端”的研发服务平台，能够顺应药物研发价值链，从早期药物发现阶段开始为客户提供服务，并在客户项目不断推进的过程中，从“跟随项目发展”到“跟随药物分子发展”，不断扩大服务，获得持续的增长。分析人士认为，药明康德与全球制药行业发展以及新药研发投入密切相关，在全球制药行业蓬勃发展的推动下，公司的主营业务有着广阔的发展空间，伴随着全球各国经济的发展、全球人口总量的增长、人口老龄化程度的提高、科技进步、医疗开支上升以及大众对于健康生活的需求不断增强，预计全球制药市场规模以及对于医药研发服务的需求仍然将持续增长。数据显示，截至2024年末，药明康德整体活跃客户约6000家。其中，持续经营业务截至年末活跃客户约5500家，持续经营业务全年新增客户约1000家，全球各地客户对公司服务的需求持续增长。截至2024年末，公司持续经营业务在手订单人民币493.1亿元，同比增长47.0%。","news_type":1,"symbols_score_info":{"603259":1.1,"02359":1.1}},"isVote":1,"tweetType":1,"viewCount":833,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
